
|Videos|March 4, 2022
Dr. Spiess discusses differences in MTAP incidence and deletion across various tumors
Author(s)Urology Times staff
“We need to look at tumors a little bit differently. Not so much put them in the same categories, but really look at them based on whether the mutation is as identified in that specific marker,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.
Advertisement
In this video, Philippe E. Spiess, MD, MS, FRCSC, FACS, discusses the background and findings of the study, “Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Spiess is a genitourinary oncologist and assistant chief of surgical services at the Moffitt Cancer Center in Tampa, Florida.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












